Notably, FTO inhibition using this pharmacological inhibitor CS1 resulted in a dose- and time-dependent decrease in viability of MiaPaCa2, Panc1, and BxPC3 pancreatic cancer cells (Figure 1C). The gene discussed is FTO; the disease is familial pancreatic carcinoma.